Biopharmaceuticals: Approval trends in 2005

Research output: Contribution to journal › Review article › peer-review

Abstract

Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{9cc5049f78214159812beb49baad0783,

title = "Biopharmaceuticals: Approval trends in 2005",

abstract = "Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.",

author = "Gary Walsh",

year = "2006",

month = aug,

language = "English",

volume = "19",

pages = "58--68",

journal = "BioPharm International",

issn = "1542-166X",

number = "8",

}

TY - JOUR

T1 - Biopharmaceuticals

T2 - Approval trends in 2005

AU - Walsh, Gary

PY - 2006/8

Y1 - 2006/8

N2 - Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

AB - Ten biopharmaceuticals gained marketing approval in the US and EU in 2005, although only five were genuinely new molecular entities.

UR - http://www.scopus.com/inward/record.url?scp=33747164744&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:33747164744

SN - 1542-166X

VL - 19

SP - 58

EP - 68

JO - BioPharm International

JF - BioPharm International

IS - 8

ER -